株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

肝臓癌:診断機器のパイプライン分析

Liver Cancer - Pipeline Review, 2015

発行 GlobalData 商品コード 146458
出版日 ページ情報 英文 76 Pages
即納可能
価格
本日の銀行送金レート: 1USD=114.71円で換算しております。
Back to Top
肝臓癌:診断機器のパイプライン分析 Liver Cancer - Pipeline Review, 2015
出版日: 2015年10月01日 ページ情報: 英文 76 Pages
概要

当レポートでは、世界各国の企業・医療機関などで開発中の、肝臓癌向け診断機器のパイプライン製品情報について分析し、治験/製品開発の全体的な進行状況や、段階別・分野別・地域別の詳細動向、企業別・製品別の詳細情報 (治験の進行段階、開始/終了時期、認証見通しなど)、昨今の製品開発の動き・業界動向などを盛り込んでお届けいたします。

第1章 目次

第2章 イントロダクション

  • 肝臓癌の概要

第3章 開発中の製品

  • パイプライン製品:開発段階別
  • パイプライン製品:地域別
  • パイプライン製品:規制経路別
  • パイプライン製品:認証時期別 (推定)

第4章 肝臓癌用診断機器:開発中のパイプライン製品 (企業別)

  • 肝臓癌治療薬の開発企業:パイプライン製品 (開発段階別)
  • 肝臓癌治療薬:開発段階別のパイプライン製品の一覧

第5章 肝臓癌用診断機器の開発企業・製品の概要

  • Abbott Diagnostics
    • パイプライン製品および進行中の治験の概要
  • Almac Diagnostics Limited
  • AXO Science S.A.S.
  • BioMark Technologies Inc.
  • China Sky One Medical, Inc.
  • Digna Biotech, S.L.
  • Drexel University
  • German Cancer Research Center
  • Glycotest, Inc.
  • IntegraGen SA
  • Matrix-Bio, Inc.
  • NanoString Technologies, Inc.
  • National Cancer Institute
  • Orion Genomics LLC
  • PleX Diagnostics
  • ProMIS Neurosciences Inc.
  • Proplex Technologies, Llc
  • Proteome Sciences Plc
  • Roche Diagnostics International Ltd.
  • TrovaGene, Inc.
  • University of Chicago
  • University of Rochester
  • Viomics Inc.
  • XEPTAGEN SpA
  • Xiamen Zeesan Biotech Co.,Ltd

第6章 肝臓癌用診断機器:昨今の市場動向

第7章 付録

図表一覧

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GDME0070EPD

GlobalData's Medical Devices sector report, "Liver Cancer - Pipeline Review, 2015" provides an overview of Liver Cancer diagnostic tests currently in pipeline stage.

The report provides comprehensive information on the pipeline products with comparative analysis of the products at various stages of development. The report reviews major players involved in the pipeline product development. It also provides information about clinical trials in progress, which includes trial phase, trial status, trial start and end dates, and, the number of trials for the key Liver Cancer diagnostic tests pipeline products.

This report is prepared using data sourced from in-house databases, secondary and primary research by GlobalData's team of industry experts.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data in relation to the equipment type.

Scope

  • Extensive coverage of the Liver Cancer diagnostic tests under development
  • The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities
  • The report reviews the major players involved in the development of Liver Cancer diagnostic tests and list all their pipeline projects
  • The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage
  • The report provides key clinical trial data of ongoing trials specific to pipeline products
  • Recent developments in the segment / industry

Reasons to buy

The report enables you to -

  • Formulate significant competitor information, analysis, and insights to improve R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of Liver Cancer diagnostic tests under development
  • Develop market-entry and market expansion strategies
  • Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline
  • In-depth analysis of the product's current stage of development, territory and estimated launch date

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Liver Cancer Overview

3. Products under Development

  • 3.1. Liver Cancer - Pipeline Products by Stage of Development
  • 3.2. Liver Cancer - Pipeline Products by Territory
  • 3.3. Liver Cancer - Pipeline Products by Regulatory Path
  • 3.4. Liver Cancer - Pipeline Products by Estimated Approval Date

4. Liver Cancer - Pipeline Products under Development by Companies

  • 4.1. Liver Cancer Companies - Pipeline Products by Stage of Development
  • 4.2. Liver Cancer - Pipeline Products by Stage of Development

5. Liver Cancer Companies and Product Overview

  • 5.1. Abbott Diagnostics Company Overview
    • 5.1.1. Abbott Diagnostics Pipeline Products & Ongoing Clinical Trials Overview
  • 5.2. Almac Diagnostics Limited Company Overview
    • 5.2.1. Almac Diagnostics Limited Pipeline Products & Ongoing Clinical Trials Overview
  • 5.3. AXO Science S.A.S. Company Overview
    • 5.3.1. AXO Science S.A.S. Pipeline Products & Ongoing Clinical Trials Overview
  • 5.4. BioMark Technologies Inc. Company Overview
    • 5.4.1. BioMark Technologies Inc. Pipeline Products & Ongoing Clinical Trials Overview
  • 5.5. China Sky One Medical, Inc. Company Overview
    • 5.5.1. China Sky One Medical, Inc. Pipeline Products & Ongoing Clinical Trials Overview
  • 5.6. Digna Biotech, S.L. Company Overview
    • 5.6.1. Digna Biotech, S.L. Pipeline Products & Ongoing Clinical Trials Overview
  • 5.7. Drexel University Company Overview
    • 5.7.1. Drexel University Pipeline Products & Ongoing Clinical Trials Overview
  • 5.8. German Cancer Research Center Company Overview
    • 5.8.1. German Cancer Research Center Pipeline Products & Ongoing Clinical Trials Overview
  • 5.9. Glycotest, Inc. Company Overview
    • 5.9.1. Glycotest, Inc. Pipeline Products & Ongoing Clinical Trials Overview
  • 5.10. Imperial College London Company Overview
    • 5.10.1. Imperial College London Pipeline Products & Ongoing Clinical Trials Overview
  • 5.11. IntegraGen SA Company Overview
    • 5.11.1. IntegraGen SA Pipeline Products & Ongoing Clinical Trials Overview
  • 5.12. Matrix-Bio, Inc. Company Overview
    • 5.12.1. Matrix-Bio, Inc. Pipeline Products & Ongoing Clinical Trials Overview
  • 5.13. NanoString Technologies, Inc. Company Overview
    • 5.13.1. NanoString Technologies, Inc. Pipeline Products & Ongoing Clinical Trials Overview
  • 5.14. National Cancer Institute Company Overview
    • 5.14.1. National Cancer Institute Pipeline Products & Ongoing Clinical Trials Overview
  • 5.15. Orion Genomics LLC Company Overview
    • 5.15.1. Orion Genomics LLC Pipeline Products & Ongoing Clinical Trials Overview
  • 5.16. PleX Diagnostics Company Overview
    • 5.16.1. PleX Diagnostics Pipeline Products & Ongoing Clinical Trials Overview
  • 5.17. ProMIS Neurosciences Inc. Company Overview
    • 5.17.1. ProMIS Neurosciences Inc. Pipeline Products & Ongoing Clinical Trials Overview
  • 5.18. Proplex Technologies, Llc Company Overview
    • 5.18.1. Proplex Technologies, Llc Pipeline Products & Ongoing Clinical Trials Overview
  • 5.19. Proteome Sciences Plc Company Overview
    • 5.19.1. Proteome Sciences Plc Pipeline Products & Ongoing Clinical Trials Overview
  • 5.20. Roche Diagnostics International Ltd. Company Overview
    • 5.20.1. Roche Diagnostics International Ltd. Pipeline Products & Ongoing Clinical Trials Overview
  • 5.21. TrovaGene, Inc. Company Overview
    • 5.21.1. TrovaGene, Inc. Pipeline Products & Ongoing Clinical Trials Overview
  • 5.22. University of Chicago Company Overview
    • 5.22.1. University of Chicago Pipeline Products & Ongoing Clinical Trials Overview
  • 5.23. University of Rochester Company Overview
    • 5.23.1. University of Rochester Pipeline Products & Ongoing Clinical Trials Overview
  • 5.24. Viomics Inc. Company Overview
    • 5.24.1. Viomics Inc. Pipeline Products & Ongoing Clinical Trials Overview
  • 5.25. XEPTAGEN SpA Company Overview
    • 5.25.1. XEPTAGEN SpA Pipeline Products & Ongoing Clinical Trials Overview
  • 5.26. Xiamen Zeesan Biotech Co.,Ltd Company Overview
    • 5.26.1. Xiamen Zeesan Biotech Co.,Ltd Pipeline Products & Ongoing Clinical Trials Overview

6. Liver Cancer- Recent Developments

7. Appendix

  • 7.1. Methodology
  • 7.2. About GlobalData
  • 7.3. Contact Us
  • 7.4. Disclaimer

List of Tables

  • Table 1: Liver Cancer - Pipeline Products by Stage of Development
  • Table 2: Liver Cancer - Pipeline Products by Territory
  • Table 3: Liver Cancer - Pipeline Products by Regulatory Path
  • Table 4: Liver Cancer - Pipeline Products by Estimated Approval Date
  • Table 5: Liver Cancer Companies - Pipeline Products by Stage of Development
  • Table 6: Liver Cancer - Pipeline Products by Stage of Development
  • Table 7: Abbott Diagnostics Pipeline Products & Ongoing Clinical Trials Overview
  • Table 8: ARCHITECT c16000 System - PIVKA Assay - Product Status
  • Table 9: ARCHITECT c16000 System - PIVKA Assay - Product Description
  • Table 10: ARCHITECT c4000 System - PIVKA Assay - Product Status
  • Table 11: ARCHITECT c4000 System - PIVKA Assay - Product Description
  • Table 12: ARCHITECT c8000 System - PIVKA Assay - Product Status
  • Table 13: ARCHITECT c8000 System - PIVKA Assay - Product Description
  • Table 14: ARCHITECT ci16200 Integrated System - PIVKA Assay - Product Status
  • Table 15: ARCHITECT ci16200 Integrated System - PIVKA Assay - Product Description
  • Table 16: ARCHITECT ci4100 Integrated System - PIVKA Assay - Product Status
  • Table 17: ARCHITECT ci4100 Integrated System - PIVKA Assay - Product Description
  • Table 18: ARCHITECT ci8200 Integrated System - PIVKA Assay - Product Status
  • Table 19: ARCHITECT ci8200 Integrated System - PIVKA Assay - Product Description
  • Table 20: Almac Diagnostics Limited Pipeline Products & Ongoing Clinical Trials Overview
  • Table 21: Prognostic Test - NSCLC - Product Status
  • Table 22: Prognostic Test - NSCLC - Product Description
  • Table 23: AXO Science S.A.S. Pipeline Products & Ongoing Clinical Trials Overview
  • Table 24: Multiplexed Detection - Des-Carboxy Prothrombin - Product Status
  • Table 25: Multiplexed Detection - Des-Carboxy Prothrombin - Product Description
  • Table 26: Multiplexed Detection - Matrix metalloproteinase 1 - Product Status
  • Table 27: Multiplexed Detection - Matrix metalloproteinase 1 - Product Description
  • Table 28: Multiplexed Detection - Procollagen type III N-terminal peptide - Product Status
  • Table 29: Multiplexed Detection - Procollagen type III N-terminal peptide - Product Description
  • Table 30: BioMark Technologies Inc. Pipeline Products & Ongoing Clinical Trials Overview
  • Table 31: Biomarker Assay - Hepatocellular Cancer - Product Status
  • Table 32: Biomarker Assay - Hepatocellular Cancer - Product Description
  • Table 33: China Sky One Medical, Inc. Pipeline Products & Ongoing Clinical Trials Overview
  • Table 34: Diagnostic Kit - Liver Cancer - Product Status
  • Table 35: Diagnostic Kit - Liver Cancer - Product Description
  • Table 36: Digna Biotech, S.L. Pipeline Products & Ongoing Clinical Trials Overview
  • Table 37: HCC Molecular Marker Assay - Product Status
  • Table 38: HCC Molecular Marker Assay - Product Description
  • Table 39: Oxidated APO-A1 Assay - Product Status
  • Table 40: Oxidated APO-A1 Assay - Product Description
  • Table 41: Drexel University Pipeline Products & Ongoing Clinical Trials Overview
  • Table 42: Diagnostic Test - Liver Cancer - Product Status
  • Table 43: Diagnostic Test - Liver Cancer - Product Description
  • Table 44: Glycan-Based Biomarker Assay - Liver Cancer - Product Status
  • Table 45: Glycan-Based Biomarker Assay - Liver Cancer - Product Description
  • Table 46: German Cancer Research Center Pipeline Products & Ongoing Clinical Trials Overview
  • Table 47: RAGE Based Diagnostic Assay - Liver Cancer - Product Status
  • Table 48: RAGE Based Diagnostic Assay - Liver Cancer - Product Description
  • Table 49: Glycotest, Inc. Pipeline Products & Ongoing Clinical Trials Overview
  • Table 50: Diagnostic Test - Liver Cancer - Product Status
  • Table 51: Diagnostic Test - Liver Cancer - Product Description
  • Table 52: Imperial College London Pipeline Products & Ongoing Clinical Trials Overview
  • Table 53: Diagnostic Assay - HCC - Product Status
  • Table 54: Diagnostic Assay - HCC - Product Description
  • Table 55: IntegraGen SA Pipeline Products & Ongoing Clinical Trials Overview
  • Table 56: Diagnostic Test - Hepatocellular Carcinoma - Product Status
  • Table 57: Diagnostic Test - Hepatocellular Carcinoma - Product Description
  • Table 58: Matrix-Bio, Inc. Pipeline Products & Ongoing Clinical Trials Overview
  • Table 59: VeraMarker Liver Cancer Screening - Product Status
  • Table 60: VeraMarker Liver Cancer Screening - Product Description
  • Table 61: VeraMarker Liver Cancer Test - Product Status
  • Table 62: VeraMarker Liver Cancer Test - Product Description
  • Table 63: NanoString Technologies, Inc. Pipeline Products & Ongoing Clinical Trials Overview
  • Table 64: In Vitro Diagnostic Assay - HCC Gene Signature - Product Status
  • Table 65: In Vitro Diagnostic Assay - HCC Gene Signature - Product Description
  • Table 66: National Cancer Institute Pipeline Products & Ongoing Clinical Trials Overview
  • Table 67: HCC Gene Signature Diagnostic Test - Product Status
  • Table 68: HCC Gene Signature Diagnostic Test - Product Description
  • Table 69: HCC Gene Signature Prognostic Test - Product Status
  • Table 70: HCC Gene Signature Prognostic Test - Product Description
  • Table 71: Orion Genomics LLC Pipeline Products & Ongoing Clinical Trials Overview
  • Table 72: Diagnostic Assay - Liver Cancer - Product Status
  • Table 73: Diagnostic Assay - Liver Cancer - Product Description
  • Table 74: PleX Diagnostics Pipeline Products & Ongoing Clinical Trials Overview
  • Table 75: HCCpleX - Product Status
  • Table 76: HCCpleX - Product Description
  • Table 77: ProMIS Neurosciences Inc. Pipeline Products & Ongoing Clinical Trials Overview
  • Table 78: Screening Test - Liver Cancer - Product Status
  • Table 79: Screening Test - Liver Cancer - Product Description
  • Table 80: Proplex Technologies, Llc Pipeline Products & Ongoing Clinical Trials Overview
  • Table 81: Biomarker Diagnostic Test - Liver Cancer - Product Status
  • Table 82: Biomarker Diagnostic Test - Liver Cancer - Product Description
  • Table 83: Proteome Sciences Plc Pipeline Products & Ongoing Clinical Trials Overview
  • Table 84: Biomarker Assay - Liver Cancer - Product Status
  • Table 85: Biomarker Assay - Liver Cancer - Product Description
  • Table 86: Roche Diagnostics International Ltd. Pipeline Products & Ongoing Clinical Trials Overview
  • Table 87: Glypican-3 MAb Companion Diagnostic Test - Product Status
  • Table 88: Glypican-3 MAb Companion Diagnostic Test - Product Description
  • Table 89: TrovaGene, Inc. Pipeline Products & Ongoing Clinical Trials Overview
  • Table 90: Diagnostic Test - Liver Cancer - Product Status
  • Table 91: Diagnostic Test - Liver Cancer - Product Description
  • Table 92: University of Chicago Pipeline Products & Ongoing Clinical Trials Overview
  • Table 93: Paxillin Prognostic Biomarker - Liver Cancer - Product Status
  • Table 94: Paxillin Prognostic Biomarker - Liver Cancer - Product Description
  • Table 95: University of Rochester Pipeline Products & Ongoing Clinical Trials Overview
  • Table 96: Biomarker Test - HCC - Product Status
  • Table 97: Biomarker Test - HCC - Product Description
  • Table 98: Viomics Inc. Pipeline Products & Ongoing Clinical Trials Overview
  • Table 99: Diagnostic Assay - Liver Cancer - Product Status
  • Table 100: Diagnostic Assay - Liver Cancer - Product Description
  • Table 101: XEPTAGEN SpA Pipeline Products & Ongoing Clinical Trials Overview
  • Table 102: compleXima HCC Biochip - Liver Cancer - Product Status
  • Table 103: compleXima HCC Biochip - Liver Cancer - Product Description
  • Table 104: DCP-IgM Kit - Liver Cancer - Product Status
  • Table 105: DCP-IgM Kit - Liver Cancer - Product Description
  • Table 106: GPC3-IgM Kit - Liver Cancer - Product Status
  • Table 107: GPC3-IgM Kit - Liver Cancer - Product Description
  • Table 108: Osteopontin-IgM Kit - Liver Cancer - Product Status
  • Table 109: Osteopontin-IgM Kit - Liver Cancer - Product Description
  • Table 110: Survivin-IgM Kit - Liver Cancer - Product Status
  • Table 111: Survivin-IgM Kit - Liver Cancer - Product Description
  • Table 112: VEGF-IgM Kit - Liver Cancer - Product Status
  • Table 113: VEGF-IgM Kit - Liver Cancer - Product Description
  • Table 114: Xiamen Zeesan Biotech Co.,Ltd Pipeline Products & Ongoing Clinical Trials Overview
  • Table 115: Theranostic - Liver Cancer Metastasis - Product Status
  • Table 116: Theranostic - Liver Cancer Metastasis - Product Description
  • Table 117: Glossary

List of Figures

  • Figure 1: Liver Cancer - Pipeline Products by Stage of Development
  • Figure 2: Liver Cancer - Pipeline Products by Territory
  • Figure 3: Liver Cancer - Pipeline Products by Regulatory Path
  • Figure 4: Liver Cancer - Pipeline Products by Estimated Approval Date
Back to Top